Discovery of highly potent and selective 7-ethyl-10-hydroxycamptothecin-glucose conjugates as potential anti-colorectal cancer agents

7-Ethyl-10-hydroxycamptothecin (SN38), a highly potent metabolite of irinotecan, has an anticancer efficacy 100-1000 folds more than irinotecan . However, the clinical application of SN38 has been limited due to the very narrow therapeutic window and poor water solubility. Herein, we report the SN38...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in pharmacology 2022-11, Vol.13, p.1014854-1014854
Main Authors: Yang, Chao, Xia, An-Jie, Du, Cheng-Hao, Hu, Ming-Xing, Gong, You-Ling, Tian, Rong, Jiang, Xin, Xie, Yong-Mei
Format: Article
Language:English
Subjects:
7-ethyl-10-hydroxycamptothecin
anticancer
colorectal cancer
glucose conjugates
Pharmacology
warburg effect
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:7-Ethyl-10-hydroxycamptothecin (SN38), a highly potent metabolite of irinotecan, has an anticancer efficacy 100-1000 folds more than irinotecan . However, the clinical application of SN38 has been limited due to the very narrow therapeutic window and poor water solubility. Herein, we report the SN38-glucose conjugates (Glu-SN38) that can target cancer cells due to their selective uptake glucose transporters, which are overexpressed in most cancers. The antiproliferative activities against human cancer cell lines and normal cells of Glu-SN38 were investigated. One of the conjugates named showed high potency and selectivity against human colorectal cancer cell line HCT116. Furthermore, remarkably inhibited the growth of HCT116 . These results suggested that could be a promising drug candidate for treating colorectal cancer.
ISSN:1663-9812
1663-9812
DOI:10.3389/fphar.2022.1014854